Disruption of p16INK4A in mice leads to increased risk of osteosarcomas, histiocytic lymphomas and melanomas and inactivation of INK4A in humans is found in approximately 30% of the most common cancers (Kim and Sharpless, 2006). This evidence concerns the gene CDKN2A and cancer.